{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:57:42Z","timestamp":1793833062575,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tertiary lymphoid structure (TLS) contributes to the anti-tumor immune response, and predicts the prognosis of colorectal cancer patients. However, the potential impact of TLS in shaping the immune status of rectal adenocarcinoma, and the intrinsic relationship between TLS and neoadjuvant therapies (neoTx) remain unclear. We performed hematoxylin-eosin staining, immunohistochemical and biomolecular analyses to investigate TLS and tumor-infiltrating lymphocytes (TILs) in 221 neoTx-treated and 242 treatment-na\u00efve locally advanced rectal cancer (LARC) patients. High TLS density was significantly associated with the absence of vascular invasion, a lower neutrophil-to-lymphocyte ratio, increased TLS maturity, a longer recurrence-free survival (RFS) (hazard ratio [HR] 0.2985 95% confidence interval [CI] 0.1894\u20130.4706, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and enhanced infiltration of adaptive immune cells. Biomolecular analysis showed that high TLS-score was strongly associated with more infiltration of immune cells and increased activation of immune-related pathways. TLS<jats:sup>+<\/jats:sup> tumors in pre-treatment specimens were associated with a higher proportion of good respond (62.5% vs. 29.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0002) and pathological complete remission (pCR) (40.0% vs. 11.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and significantly increased RFS (HR 0.3574 95%CI 0.1489\u20130.8578 <jats:italic>p<\/jats:italic>\u2009=\u20090.0213) compared with TLS<jats:sup>-<\/jats:sup> tumors in the neoTx cohort, which was confirmed in GSE119409 and GSE150082. Further studies showed that neoTx significantly reduced TLS density and maturity, and abolished the prognostic value of TLS. Our study illustrates that TLS may have a key role in mediating the T-cell-inflamed tumor microenvironment, which also provides a new direction for neoTx, especially neoadjuvant immunotherapy, in LRAC patients.<\/jats:p>","DOI":"10.1038\/s41698-024-00533-w","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T13:01:33Z","timestamp":1709384493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-8847","authenticated-orcid":false,"given":"Qianyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-1898","authenticated-orcid":false,"given":"Wentao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-1814","authenticated-orcid":false,"given":"Xiaofei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-4271","authenticated-orcid":false,"given":"Junfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"533_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"533_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"533_CR3","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128\u20132139 (2018).","journal-title":"Lancet"},{"key":"533_CR4","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"533_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"533_CR6","doi-asserted-by":"publisher","first-page":"962056","DOI":"10.3389\/fimmu.2022.962056","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer. Front Immunol. 13, 962056 (2022).","journal-title":"Front Immunol."},{"key":"533_CR7","doi-asserted-by":"publisher","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson, A. B. et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 16, 874\u2013901 (2018).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"533_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41379-020-0619-8","volume":"34","author":"L Farchoukh","year":"2021","unstructured":"Farchoukh, L. et al. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma. Mod. Pathol. 34, 171\u2013183 (2021).","journal-title":"Mod. Pathol."},{"key":"533_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-49","volume":"6","author":"K Yasuda","year":"2011","unstructured":"Yasuda, K., Nirei, T., Sunami, E., Nagawa, H. & Kitayama, J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat. Oncol. 6, 49 (2011).","journal-title":"Radiat. Oncol."},{"key":"533_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/bjs.11179","volume":"106","author":"T Akiyoshi","year":"2019","unstructured":"Akiyoshi, T. et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br. J. Surg. 106, 1381\u20131392 (2019).","journal-title":"Br. J. Surg."},{"key":"533_CR11","doi-asserted-by":"publisher","first-page":"e2252140","DOI":"10.1001\/jamanetworkopen.2022.52140","volume":"6","author":"T Akiyoshi","year":"2023","unstructured":"Akiyoshi, T. et al. Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer. JAMA Netw. Open 6, e2252140 (2023).","journal-title":"JAMA Netw. Open"},{"key":"533_CR12","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila, W. K. et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat. Med 28, 1646\u20131655 (2022).","journal-title":"Nat. Med"},{"key":"533_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509\u2013528 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"533_CR14","doi-asserted-by":"publisher","first-page":"e1378844","DOI":"10.1080\/2162402X.2017.1378844","volume":"7","author":"F Posch","year":"2018","unstructured":"Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7, e1378844 (2018).","journal-title":"Oncoimmunology"},{"key":"533_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ijc.32982","volume":"147","author":"R Tokunaga","year":"2020","unstructured":"Tokunaga, R. et al. 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. Int J. Cancer 147, 532\u2013541 (2020).","journal-title":"Int J. Cancer"},{"key":"533_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3389\/fimmu.2018.01578","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol. 9, 1578 (2018).","journal-title":"Front Immunol."},{"key":"533_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.annonc.2022.07.1942","volume":"33","author":"B Saberzadeh-Ardestani","year":"2022","unstructured":"Saberzadeh-Ardestani, B. et al. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. Ann Oncol 33, 1159\u20131167 (2022).","journal-title":"Ann Oncol"},{"key":"533_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00262-021-03076-2","volume":"71","author":"J-N Guo","year":"2022","unstructured":"Guo, J.-N. et al. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer. Cancer Immunol. Immunother. 71, 1313\u20131330 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"533_CR19","doi-asserted-by":"publisher","first-page":"e26836","DOI":"10.4161\/onci.26836","volume":"2","author":"J Goc","year":"2013","unstructured":"Goc, J., Fridman, W.-H., Saut\u00e8s-Fridman, C. & Dieu-Nosjean, M.-C. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2, e26836 (2013).","journal-title":"Oncoimmunology"},{"key":"533_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1148-6","volume":"21","author":"P J\u00e9z\u00e9quel","year":"2019","unstructured":"J\u00e9z\u00e9quel, P. et al. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res 21, 65 (2019).","journal-title":"Breast Cancer Res"},{"key":"533_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8114","volume":"6","author":"JD Peske","year":"2015","unstructured":"Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).","journal-title":"Nat. Commun."},{"key":"533_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-immunol-032713-120252","volume":"33","author":"CD Buckley","year":"2015","unstructured":"Buckley, C. D., Barone, F., Nayar, S., B\u00e9n\u00e9zech, C. & Caama\u00f1o, J. Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu Rev. Immunol. 33, 715\u2013745 (2015).","journal-title":"Annu Rev. Immunol."},{"key":"533_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fimmu.2016.00477","volume":"7","author":"F Barone","year":"2016","unstructured":"Barone, F. et al. Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation. Front Immunol. 7, 477 (2016).","journal-title":"Front Immunol."},{"key":"533_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jaad.2021.11.060","volume":"86","author":"WR Heymann","year":"2022","unstructured":"Heymann, W. R. The neutrophil-to-lymphocyte ratio in cutaneous oncology: Simply elegant. J. Am. Acad. Dermatol 86, 533\u2013534 (2022).","journal-title":"J. Am. Acad. Dermatol"},{"key":"533_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/bjc.2015.61","volume":"112","author":"ZY Chen","year":"2015","unstructured":"Chen, Z. Y. et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br. J. Cancer 112, 1088\u20131097 (2015).","journal-title":"Br. J. Cancer"},{"key":"533_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/bjc.2013.346","volume":"109","author":"G Absenger","year":"2013","unstructured":"Absenger, G. et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br. J. Cancer 109, 395\u2013400 (2013).","journal-title":"Br. J. Cancer"},{"key":"533_CR27","doi-asserted-by":"publisher","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, https:\/\/doi.org\/10.1016\/j.ccell.2022.02.002 (2022).","DOI":"10.1016\/j.ccell.2022.02.002"},{"key":"533_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"533_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"533_CR30","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao, J. et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 26, 1845\u20131851 (2020).","journal-title":"Nat. Med"},{"key":"533_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4143\/crt.2016.215","volume":"49","author":"IH Song","year":"2017","unstructured":"Song, I. H. et al. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 49, 399\u2013407 (2017).","journal-title":"Cancer Res Treat."},{"key":"533_CR32","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien, C. et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest 123, 2873\u20132892 (2013).","journal-title":"J. Clin. Invest"},{"key":"533_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cac2.12447","volume":"43","author":"F Bertucci","year":"2023","unstructured":"Bertucci, F., De Nonneville, A., Finetti, P. & Mamessier, E. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer. Cancer Commun. (Lond.) 43, 943\u2013946 (2023).","journal-title":"Cancer Commun. (Lond.)"},{"key":"533_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1346","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clin. Transl. Med. 13, e1346 (2023).","journal-title":"Clin. Transl. Med"},{"key":"533_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.annonc.2022.06.007","volume":"33","author":"M Brunet","year":"2022","unstructured":"Brunet, M. et al. Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Ann. Oncol. 33, 1084\u20131085 (2022).","journal-title":"Ann. Oncol."},{"key":"533_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Sili\u0146a","year":"2018","unstructured":"Sili\u0146a, K. et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 78, 1308\u20131320 (2018).","journal-title":"Cancer Res"},{"key":"533_CR37","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2217\/fon-2022-0061","volume":"18","author":"M Shi","year":"2022","unstructured":"Shi, M., Chen, Y. & Ji, D. The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer. Future Oncol. 18, 3229\u20133244 (2022).","journal-title":"Future Oncol."},{"key":"533_CR38","doi-asserted-by":"publisher","unstructured":"Seo, I. et al. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-001610 (2021).","DOI":"10.1136\/jitc-2020-001610"},{"key":"533_CR39","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med"},{"key":"533_CR40","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853\u20131860 (2018).","journal-title":"Ann. Oncol."},{"key":"533_CR41","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","volume":"36","author":"AB Rodriguez","year":"2021","unstructured":"Rodriguez, A. B. et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).","journal-title":"Cell Rep."},{"key":"533_CR42","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Alonso, S. et al. A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-001187 (2020).","DOI":"10.1136\/jitc-2020-001187"},{"key":"533_CR43","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/ijc.28533","volume":"134","author":"JP V\u00e4yrynen","year":"2014","unstructured":"V\u00e4yrynen, J. P. et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J. Cancer 134, 2126\u20132135 (2014).","journal-title":"Int J. Cancer"},{"key":"533_CR44","unstructured":"Amin, M. B. et al. AJCC cancer staging manual. 1024 (Springer, 2017)."},{"key":"533_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","volume":"179","author":"D Coppola","year":"2011","unstructured":"Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37\u201345 (2011).","journal-title":"Am. J. Pathol."},{"key":"533_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00533-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00533-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00533-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T14:07:09Z","timestamp":1709388429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00533-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00533-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}